Mankind Pharma Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Mankind Pharma Limited Pharmaceutical Export Portfolio Dataset — 15 Products, $58.3M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Mankind Pharma Limited — Pharmaceutical Exporter Profile (2026) | 15 Products, $58.3M Trade | TransData Nexus

Mankind Pharma Limited

Indian Pharmaceutical Exporter · Advanced Antibiotics Specialist · $58.3M Total Trade · DGFT Verified

Mankind Pharma Limited is an Indian pharmaceutical exporter with a total trade value of $58.3M across 15 products in 10 therapeutic categories. Based on 1,614 verified export shipments from Indian Customs (DGFT) records, Mankind Pharma Limited is the #1 Indian exporter in 5 products including Nitrofurantoin, Phenylephrine, Tobramycin. Top exports include Nitrofurantoin ($11.1M), Formoterol ($8.6M), Phenylephrine ($7.0M).

Mankind Pharma Limited — Export Portfolio & Destination Treemap

Mankind Pharma Limited pharmaceutical export portfolio — 15 products across 10 therapeutic categories. Source: Indian Customs (DGFT).

Who is Mankind Pharma Limited? — Company Overview & Market Position

Mankind Pharma Limited, established in 1991, is a prominent Indian pharmaceutical and healthcare company headquartered in New Delhi. The company was founded by brothers Ramesh C. Juneja and Rajeev Juneja, who began operations with a seed capital of ₹20,000 and a team of 20 employees. Over the years, Mankind Pharma has expanded its product portfolio to include pharmaceuticals, generic drugs, over-the-counter (OTC) products, fast-moving consumer goods (FMCG), and diagnostics.

As of 2023, Mankind Pharma operates 25 manufacturing facilities and 6 research and development centers across India. The company employs over 22,000 individuals, reflecting its significant presence in the pharmaceutical industry. In the fiscal year ending March 31, 2025, Mankind Pharma reported a revenue of ₹10,335 crore, with domestic revenue accounting for ₹9,522 crore. The company's registered office is located at 208, Okhla Industrial Estate, Phase-III, New Delhi, Delhi - 110020.

What Does Mankind Pharma Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Nitrofurantoin$11.1M 2

Product Portfolio — Top 15 by Export Value

Mankind Pharma Limited exports 15 pharmaceutical products across 10 therapeutic categories. Market leader (#1 exporter) in 5 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Nitrofurantoin	Advanced Antibiotics	$11.1M	225	29.4%	1
2	Formoterol	Respiratory	$8.6M	172	15.0%	2
3	Phenylephrine	Respiratory & OTC	$7.0M	140	7.9%	1
4	Ofloxacin	Advanced Antibiotics	$6.1M	160	2.1%	9
5	Vati	Ayurvedic & Herbal Products	$4.6M	159	15.5%	2
6	Tobramycin	Antibiotics	$4.2M	84	9.9%	1
7	Fenofibrate	Lipid & Metabolism	$4.2M	283	5.7%	7
8	Omega	Nutritional Supplements	$3.8M	84	20.0%	2
9	Capecitabine	Advanced Oncology	$2.9M	58	3.3%	1
10	Terbinafine	Antifungals	$2.0M	111	7.2%	4
11	Ephedrine	Respiratory & OTC	$1.4M	27	6.0%	1
12	Verapamil	Cardiovascular	$836.9K	21	0.8%	8
13	Nitroglycerin	Cardiovascular	$728.5K	57	7.5%	4
14	Moxifloxacin	Advanced Antibiotics	$452.0K	11	1.4%	10
15	Itraconazole	Antifungals	$418.1K	22	1.5%	15

Mankind Pharma Limited exports 15 pharmaceutical products across 10 therapeutic categories with a total export value of $58.3M. The company is the #1 Indian exporter in 5 products: Nitrofurantoin, Phenylephrine, Tobramycin, Capecitabine, Ephedrine. The top category is Advanced Antibiotics (30.4% of portfolio), followed by Respiratory (14.8%), indicating a concentrated portfolio with the top 5 products accounting for 64.3% of total export value.

Mankind Pharma Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Mankind Pharma's manufacturing operations are extensive, with 25 factories strategically located across India. These facilities are equipped to produce a wide range of pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's manufacturing plants adhere to stringent quality standards, ensuring the production of safe and effective medications. Specific details regarding the capacities and specializations of each plant are proprietary and not publicly disclosed.

3Key Leadership

The leadership team at Mankind Pharma is headed by Chairman and Managing Director Ramesh C. Juneja, who co-founded the company and has been instrumental in its growth and success. Rajeev Juneja serves as the Vice Chairman and Managing Director, contributing significantly to the company's strategic direction and operations. Sheetal Arora holds the position of Chief Executive Officer, overseeing the company's day-to-day operations and ensuring alignment with its long-term objectives. Other key executives include Arjun Juneja, the Chief Operating Officer, and Pradeep Chugh, the Company Secretary and Compliance Officer.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Mankind Pharma Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Mankind Pharma has made significant strides in regulated markets, particularly in the United States. In June 2021, the company launched Justoza, a Dapagliflozin brand approved by the US FDA, marking its entry into the US market. The Active Pharmaceutical Ingredient (API) for Justoza is sourced from a US FDA-approved Drug Master File (DMF) facility, ensuring adherence to global efficacy and safety standards. While specific details regarding regulatory filings and approvals in the European Union, United Kingdom, Australia, and Japan are not publicly available, Mankind Pharma's commitment to quality and compliance suggests a proactive approach to meeting international regulatory requirements.

2Emerging Markets

Mankind Pharma has expanded its presence in emerging markets, including Africa, Latin America, and Southeast Asia. The company's diverse product portfolio, encompassing pharmaceuticals, OTC products, and FMCG items, positions it well to cater to the healthcare needs of these regions. In November 2025, Mankind Pharma entered into a licensing agreement with Actimed Therapeutics Ltd, granting exclusive rights to develop and commercialize Actimed's products for the treatment and prevention of cachexia in India and South Asian territories. This strategic move underscores Mankind Pharma's commitment to addressing critical health issues in emerging markets.

Geographic Strategy

Mankind Pharma Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Mankind Pharma has demonstrated its commitment to meeting international standards by obtaining FDA approval for its product Justoza, a Dapagliflozin brand launched in June 2021. The API for Justoza is sourced from a US FDA-approved DMF facility, ensuring compliance with global efficacy and safety standards. Specific details regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. However, the approval of Justoza indicates a proactive approach by Mankind Pharma in adhering to FDA regulations.

2WHO & EU GMP

Mankind Pharma's commitment to quality is evident in its adherence to Good Manufacturing Practices (GMP) standards. The company sources its APIs from facilities that are approved by the World Health Organization (WHO) and the European Union (EU) GMP, ensuring compliance with international quality standards. While specific details regarding WHO prequalification and EU GMP certificates are not publicly available, the company's sourcing practices reflect a dedication to maintaining high-quality manufacturing processes.

3CDSCO & Indian Regulatory

Mankind Pharma Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Mankind Pharma operates in a competitive landscape, with several key players in the Indian pharmaceutical industry. While specific market share data is not publicly available, Mankind Pharma's diverse product portfolio and strategic initiatives position it as a significant competitor in both domestic and international markets. The company's focus on affordability, quality, and accessibility has contributed to its growth and competitive standing.

2Key Differentiators

Mankind Pharma's key differentiators include its extensive product portfolio, encompassing pharmaceuticals, OTC products, and FMCG items, catering to a wide range of consumer needs. The company's commitment to affordability, quality, and accessibility has facilitated its growth and market penetration. Strategic initiatives, such as the licensing agreement with Actimed Therapeutics Ltd in November 2025, demonstrate Mankind Pharma's proactive approach to addressing critical health issues and expanding its product offerings.

3Strategic Position

Mankind Pharma's current strategic direction focuses on expanding its presence in both domestic and international markets. The company's diverse product portfolio, including generics, specialty products, and OTC items, reflects a balanced approach to addressing various market segments. Future outlooks suggest continued growth through strategic partnerships, such as the licensing agreement with Actimed Therapeutics Ltd, and potential expansions into new therapeutic areas and markets.

Buyer Due Diligence Brief — Evaluating Mankind Pharma Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Mankind Pharma's supplier assessment indicates a strong track record in sourcing high-quality APIs from facilities approved by international regulatory bodies, including the US FDA, EU GMP, and WHO GMP. The company's proactive approach to quality assurance and regulatory compliance suggests reliability and consistency in its supply chain operations. While specific export volumes and consistency metrics are not publicly disclosed, Mankind Pharma's extensive domestic and international operations reflect a robust and dependable supply chain.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm that the product is approved by the US Food and Drug Administration (FDA). This can be verified through the FDA's official website or by contacting the manufacturer directly.

WHO-GMP Certification: Ensure that the manufacturing facility adheres to World Health Organization's Good Manufacturing Practices (GMP). This information is typically available on the manufacturer's website or can be obtained by contacting them directly.

Frequently Asked Questions — Mankind Pharma Limited

How many pharmaceutical products does Mankind Pharma Limited export from India?

Mankind Pharma Limited exports 15 pharmaceutical products across 10 therapeutic categories. The top exports are Nitrofurantoin ($11.1M), Formoterol ($8.6M), Phenylephrine ($7.0M), Ofloxacin ($6.1M), Vati ($4.6M). Total export value is $58.3M.

What is Mankind Pharma Limited's total pharmaceutical export value?

Mankind Pharma Limited's total pharmaceutical export value is $58.3M, based on 1,614 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Mankind Pharma Limited the #1 Indian exporter?

Mankind Pharma Limited is the #1 Indian exporter in 5 products: Nitrofurantoin (29.4% market share), Phenylephrine (7.9% market share), Tobramycin (9.9% market share), Capecitabine (3.3% market share), Ephedrine (6.0% market share).

What therapeutic categories does Mankind Pharma Limited cover?

Mankind Pharma Limited exports across 10 therapeutic categories. The largest are Advanced Antibiotics (30.4%, 3 products), Respiratory (14.8%, 1 products), Respiratory & OTC (14.3%, 2 products).

Get Full Mankind Pharma Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.